Analysts Are Bullish on These Healthcare Stocks: ESSA Pharma Inc (EPIX), Kamada (KMDA)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ESSA Pharma Inc (EPIX) and Kamada (KMDA) with bullish sentiments.

ESSA Pharma Inc (EPIX)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on ESSA Pharma Inc today and set a price target of $14. The company’s shares closed yesterday at $2.43.

Pantginis said:

“Valuation and risks to price target achievement. We reiterate our Buy rating and $14 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our current target is based 100% on the projected lead Aniten asset for prostate cancer. Factors that could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”

According to TipRanks.com, Pantginis is a 1-star analyst with an average return of -1.6% and a 35.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.

ESSA Pharma Inc has an analyst consensus of Moderate Buy, with a price target consensus of $14.

See today’s analyst top recommended stocks >>

Kamada (KMDA)

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Kamada today and set a price target of $11. The company’s shares closed yesterday at $5.73.

Fein wrote:

“Valuation and risks to achievement of target price. Our price target of $11/share is based on an equally weighted composite of: (a) $7.57/share, as a 35x multiple of taxed and diluted FY23 GAAP EPS of $0.62 discounted back to and (b) an NPV of $15.05/share (discount rate 12.5%, growth rate 1%).”

According to TipRanks.com, Fein is a 4-star analyst with an average return of 3.5% and a 44.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Currently, the analyst consensus on Kamada is a Moderate Buy with an average price target of $9, a 57.1% upside from current levels. In a report released today, Chardan Capital also reiterated a Buy rating on the stock with a $7 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts